Hong Kong · Delayed Price · Currency is HKD Biocytogen Pharmaceuticals (Beijing) Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
It operates through Five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development.
The Gene-editing services segment provides the customized gene editing services based on animals as well as cells to meet the needs of basic science research and drug development of the customers; Pre-clinical pharmacology and efficacy evaluation segment provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; Animal models selling segment breeds and sells the animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; Antibody development segment utilises the Group’s own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and Innovative drugs development segment engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.
The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial.
The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
| Country | China |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,117 |
| CEO | Yuelei Shen |
Contact Details
Address: 12 Baoshen South Street Beijing China | |
| Phone | 86 10 5696 7680 |
| Website | biocytogen.com |
Stock Details
| Ticker Symbol | 2315 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005D27 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Qingcong Lin | Deputy GM and Chief Executive Officer of Biocytogen Boston Corporate |
| Dr. Yuelei Shen Ph.D. | Chairman of the Board, Chief Executive Officer and GM |
| Dr. Jian Ni | Executive Director |
| Dr. Haichao Zhang | Senior Operation Director of Animal Center and Executive Director |
| Bin Liu | Chief Financial Officer and Deputy GM |
| Dr. Yi Yang | Chief Scientific Officer and Deputy GM |
| Chunli Sun | Director of Human Resources and Supervisor |
| Yan Li | Chairman of the Supervisory Committee and Director of the President's Office |
| Yongliang Wang | Deputy GM and Secretary |
| Wai Ching Au A.C.I.S. | Joint Company Secretary |